Table 3.
Hematological values
| ||||
---|---|---|---|---|
Variables | HAART-naïve | HAART-experienced | Total | p-value |
| ||||
Mean ± SD | Mean ± SD | Mean ± SD | ||
Hg, g/dL | 13.25±3.03 | 13.21±1.60 | 13.23±2.41 | 0.936 |
RBC, ×106/µL | 4.48±0.58 | 4.94±4.75 | 4.71±3.39 | 0.319 |
HCT, % | 38.21±4.85 | 38.43±4.00 | 38.32±4.44 | 0.708 |
MCV, fL | 86.67±13.17 | 90.10±11.6 | 87.88±12.59 | 0.008** |
MCH, pg | 29.88±5.46 | 31.11±4.07 | 30.50±4.85 | 0.057 |
MCHC, g/dL | 33.92±1.96 | 34.09±3.74 | 34.01±2.9 | 0.671 |
RDW, % | 15.11±2.57 | 14.76±2.18 | 14.94±2.39 | 0.264 |
WBC, ×103/µL | 8.18±3.32 | 8.01±3.26 | 8.09±3.29 | 0.708 |
ANC, ×103/µL | 3.94±2.26 | 3.74±2.05 | 3.84±2.16 | 0.499 |
Lymphocyte count, ×103/µL | 3.46±2.2 | 3.74±5.17 | 3.6±3.97 | 0.603 |
Mid (absolute), ×103/µL | 1.34±1.7 | 2.21±8.10 | 1.76±5.77 | 0.247 |
Neutrophil, % | 45.22±11.98 | 45.24±14 | 45.23±13.01 | 0.992 |
Lymphocyte, % | 41.31±11.67 | 41.67±12.67 | 41.49±12.21 | 0.827 |
Mid, % | 13.41±5.17 | 12.51±4.81 | 12.96±5 | 0.178 |
PLT, ×103cells/µL | 297.91±107.67 | 300.99±105.10 | 299.45±06.16 | 0.829 |
MPV, % | 9.72±1.92 | 9.82±7.96 | 9.77±5.77 | 0.899 |
CD4, cells/µL | 873.16±466.53 | 767.86±486.60 | 820.51±78.52 | 0.100 |
CD4, % | 28.73±14.22 | 24.78±10.69 | 26.73±12.71 | 0.018* |
Note:
Significant at p<0.05;
significant at p<0.01 by independent t-test analysis.
Abbreviations: ANC, absolute neutrophil count; ART, antiretroviral treatment; CD4, cluster of differentiation-4; HAART, highly active antiretroviral therapy; HCT, hematocrit; HIV, human immunodeficiency virus; Hg, hemoglobin; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; mid, mixed cell; MPV, mean platelet volume; PLT, platelets; RBC, red blood cell; RDW, red cell distribution width; SD, standard deviation; WBC, white blood cell.